- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Patent holdings for IPC class A61P 13/12
Total number of patents in this class: 5660
10-year publication summary
|
190
|
178
|
338
|
380
|
428
|
562
|
536
|
536
|
511
|
188
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1848 |
100 |
| Amicus Therapeutics, Inc. | 348 |
55 |
| Mitsubishi Tanabe Pharma Corporation | 581 |
42 |
| Boehringer Ingelheim International GmbH | 4705 |
40 |
| Novartis AG | 10975 |
39 |
| Takeda Pharmaceutical Company Limited | 2703 |
39 |
| Osaka University | 3350 |
39 |
| Eli Lilly and Company | 3795 |
33 |
| Sunshine Lake Pharma Co., Ltd. | 583 |
32 |
| F. Hoffmann-La Roche AG | 7908 |
31 |
| Tohoku University | 2749 |
31 |
| Bayer Pharma AG | 1060 |
30 |
| Vertex Pharmaceuticals Incorporated | 1586 |
30 |
| Chugai Seiyaku Kabushiki Kaisha | 1330 |
30 |
| The Regents of the University of California | 19780 |
27 |
| Mayo Foundation for Medical Education and Research | 3163 |
27 |
| Astellas Pharma Inc. | 1082 |
27 |
| Nippon Shinyaku Co., Ltd. | 328 |
27 |
| Hoffmann-La Roche Inc. | 3352 |
25 |
| AstraZeneca AB | 2933 |
25 |
| Other owners | 4931 |